DR. WILLIAM E. HAPWORTH, M.D.
Psychiatric at 57 St, New York, NY
License number
New York 146087
Category
Psychiatric
Type
Psychiatry
Address
Address
37 W 57Th St STE 1104, New York, NY 10019
Phone
(212) 956-2000
Personal information
See more information about WILLIAM E. HAPWORTH at radaris.comName
Address
Phone
40 Central Park S #3A, New York, NY 10019
41 58Th St, New York, NY 10019
40 Central Park, New York, NY 10019
220 E 57Th St #21A, New York, NY 10022
37 57Th St, New York, NY 10019
Professional information
Co-Founder At Darkhorse Investors, Thought Into Action Institute And Studysnacks.com
Position:
Co-Founder and President at DarkHorse Investors, Co-Founder and Director at Thought into Action (www.tiainstitute.com), Co-Founder and Chief Operating Officer at www.StudySnacks.com
Location:
Greater New York City Area
Industry:
Nonprofit Organization Management
Work:
DarkHorse Investors
- New York since Jun 2009
-
Co-Founder and President
Thought into Action (www.tiainstitute.com)
- New York since 2010
-
Co-Founder and Director
www.StudySnacks.com
- New York since Mar 2011
-
Co-Founder and Chief Operating Officer
Morgan Stanley
- New York May 2008 - May 2009
-
Financial Institutions Group Analyst
Morgan Stanley
- New York May 2006 - May 2008
-
Financial Sponsors Group Analyst
Colgate University
- New York Sep 2004 - Apr 2007
-
Career Service Office Recruiting Intern
Deutsche Bank
- New York Apr 2005 - Sep 2005
-
Private Wealth Managment Analyst
Amigos de las Americas
Apr 2000 - Jan 2003
-
Volunteer Experiences
Education:
Colgate University 2003 - 2007
B.A. / Magna Cum Laude, Chinese and Latin American Studies Associated Colleges in China 2005 - 2006
Phillips Academy (Andover) 1998 - 2002
B.A. / Magna Cum Laude, Chinese and Latin American Studies Associated Colleges in China 2005 - 2006
Phillips Academy (Andover) 1998 - 2002
Skills:
Financial Analysis, Bloomberg, Non-profits, Research, Start-ups, Leadership, Economics, Hedge Funds, Small Business Creation, Microsoft Excel, Capital IQ, FactSet, SNL Financial, Nonprofits, Entrepreneurship, Strategic Planning
Interests:
Micro seed investing, researching new technologies, ski-mountaineering, cycling/mountain biking, cross-fit
Honor & Awards:
Phi Eta Sigma Honor Society, Colgate University, Fall 2003
Gamma Sigma Alpha National Honor Society, Colgate University, 2006
Most Outstanding New Member, Colgate University Inter-Fraternity Community, 2005
The President’s Student Service Award. President George W. Bush 2003 / President William Clinton 2002
Phillips Academy School Term Abroad, Burgos, Spain, Winter, 2002
Languages:
Spanish, Chinese
Co-Founder And President, Darkhorse Investors
Location:
Greater New York City Area
Industry:
Nonprofit Organization Management
Dr. William E Hapworth, New York NY - MD (Doctor of Medicine)
Specialties:
Neuropsychiatry (Psychiatry)
Address:
Hapworth Center
37 W 57Th St SUITE 1104, New York 10019
(212) 956-2000 (Phone)
37 W 57Th St SUITE 1104, New York 10019
(212) 956-2000 (Phone)
Certifications:
Psychiatry, 1985
Awards:
Healthgrades Honor Roll
Languages:
English, Spanish
Hospitals:
Hapworth Center
37 W 57Th St SUITE 1104, New York 10019
Roosevelt Hospital
1000 10Th Ave, New York 10019
37 W 57Th St SUITE 1104, New York 10019
Roosevelt Hospital
1000 10Th Ave, New York 10019
Education:
Medical School
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1979
Nyu Hospitals Center
University of Medicine And Dentistry of New Jersey / Newark
Graduated: 1979
Nyu Hospitals Center
Ceo At Treatment Online Inc.
Location:
Greater New York City Area
Industry:
Health, Wellness and Fitness
Method For The Treatment Of Nicotine Withdrawal Syndrome
US Patent:
4940585, Jul 10, 1990
Filed:
Feb 17, 1989
Appl. No.:
7/312954
Inventors:
William E. Hapworth - New York NY
Mada S. Hapworth - New York NY
Mada S. Hapworth - New York NY
International Classification:
A61K 920, A61K 914, A61K 948, A61K 31135
US Classification:
424464
Abstract:
A therapeutic method for treatment of nicotine withdrawal syndrome symptoms of a patient in need thereof by administering to the patient a therapeutic composition of a pharmaceutically acceptable carrier and fluoxetine in an amount effective to provide physiological relief from the withdrawal symptoms.